Most Recent Articles by Isabel Cunningham, MD
Approaching leukemia today as only a "liquid" cancer in all cases is to overlook knowledge long available about its tumor phenotype.
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Dr Isabel Cunningham reviews and highlights important, recently published articles with recommendations for treating elderly patients with acute myeloid leukemia (AML).
Isabel Cunningham, MD, advisory board member for CTA, asks Dr Apperley about how to treat patients with CML that cause specialists particular concern.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
More Articles by Isabel Cunningham, MD
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer